
By Moira Wyton, The Tyee, Local Journalism Initiative Reporter
A British Columbia-led research group is paving the way for a landmark preventative HIV medication it hopes can reduce Canada’s stagnant rates of new HIV infections.
Long-acting pre-exposure prophylaxis, or PrEP, is more than 99 per cent effective at preventing the development of HIV when it is injected every two months, according to clinical trial data reported by manufacturer ViiV Healthcare.
The injectable drug, cabotegravir, was approved by the U.S. Food and Drug Administration last December but has not yet been submitted to Health Canada for approval.
Continue reading A Promising New Way to Prevent HIV Infections